Previous Article | Next Article 
Journal of Clinical Microbiology, June 2002, p. 2108-2114, Vol. 40, No. 6
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.6.2108-2114.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Genotyping Study of Scedosporium apiospermum Isolates from Patients with Cystic Fibrosis
Alain Defontaine,1* Rachid Zouhair,1,
Bernard Cimon,2 Jacqueline Carrère,3 Eric Bailly,4 Françoise Symoens,5 Mohammed Diouri,6 Jean-Noel Hallet,1 and Jean-Philippe Bouchara2
Laboratoire de Biotechnologie, Unité de Biocatalyse, FRE CNRS 2230, Nantes,1
Groupe d'Etude des Interactions Hôte-Parasite, UPRES-EA 3142, Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire, Angers,2
Laboratoire de Biologie, Hôpital Renée Sabran, Giens,3
Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire, Tours, France,4
Institut Scientifique de Santé Publique-Louis Pasteur, Section Mycologie, Brussels, Belgium,5
Département de Biologie, Faculté des Sciences, Université Moulay Ismail, Meknès, Morocco6
Received 26 November 2001/
Returned for modification 25 January 2002/
Accepted 26 February 2002

ABSTRACT
Usually a saprophyte,
Scedosporium apiospermum often colonizes
the respiratory tracts of patients with cystic fibrosis (CF).
In order to improve our understanding of the molecular epidemiology
of the airway colonization, 129 sequential and multiple isolates
collected from January 1998 to March 1999 from nine CF patients
monitored in three hospitals in France were typed by random
amplification of polymorphic DNA with primers GC70, UBC-701,
and UBC-703. Among these primers, UBC-703 was the most discriminating,
allowing the differentiation of 14 genotypes. Combining the
results obtained with this three-primer set resulted in the
differentiation of 16 genotypes. No common genotype was found
among the different patients, and no clustering according to
geographic origin of the isolates was seen. In addition, five
of the patients were colonized by a single genotype. The others
usually exhibited a predominant genotype accompanied by one
or two others, which were found occasionally and were genetically
close to the predominant genotype. Thus, our study demonstrates
the persistence of the fungus despite antifungal treatments
and therefore reinforces the need for the development of new
antifungals that are more efficient against this species.

INTRODUCTION
Cystic fibrosis (CF) is the most common inherited disease in
the Caucasian population; it results from mutations in the gene
CFTR, which encodes the chloride channel CF transmembrane regulator,
and is characterized by a dysfunction of the exocrine glands.
As a consequence of the resulting abnormal viscosity of the
bronchial secretions, the lungs of patients with CF are often
colonized by or infected with various bacteria, such as
Staphylococcus aureus,
Pseudomonas aeruginosa, and
Burkholderia cepacia (
9).
At a more advanced stage of the disease, the respiratory tracts
of these patients may also be colonized by filamentous fungi
because of the entrapment of airborne mold spores in the viscous
mucus and because of the bronchopulmonary epithelial tissue
damage induced by bacterial proteases and leukocyte elastase.
Besides
Aspergillus fumigatus, which remains by far the most
common species, other filamentous fungi may also be encountered.
In a large prospective study encompassing 128 CF patients monitored
during a 5-year period,
Scedosporium apiospermum was isolated
from bronchial secretions from 8.6% of the patients, ranking
it as the second most frequently occurring filamentous fungus
identified (
3).
Usually a saprophyte growing in polluted soils and sewage, this filamentous fungus may cause in humans various mycoses resulting from traumatic or iatrogenic inoculation of telluric conidia, including white-grain mycetoma, keratitis, endophthalmitis, osteomyelitis, and endocarditis (15, 21, 22). Respiratory diseases may also occur in receptive hosts, likely due to the inhalation of airborne conidia, and are similar to those described for A. fumigatus, i.e., unilateral sinusitis, necrotizing pneumonia, fungus ball in the lung, and allergic bronchopulmonary mycosis, as well as disseminated infections in severely immunocompromised hosts. More recently, attention has been paid to the particular occurrence of this fungus in CF patients (2, 3). However, its pathogenic role in this context remains controversial. In addition, little information is available concerning the epidemiology of the colonization of the airways by this fungus. In order to improve our knowledge in this field, sequential and multiple isolates from different CF patients were typed by random amplification of polymorphic DNA (RAPD) with a three-primer set previously selected for its ability to discriminate among epidemiologically unrelated strains of S. apiospermum (26).

MATERIALS AND METHODS
Patients and isolates.
From January 1998 to March 1999, all CF patients monitored in
the pediatric departments of hospitals in Angers, Giens, and
Tours (France) were surveyed for colonization of the respiratory
tract by
S. apiospermum. To this end, sputum samples collected
during the routine annual clinical visit of the patients or
during an admission to the hospital because of exacerbation
of their pulmonary disease were inoculated on yeast extract-peptone-dextrose
agar plates, which contained the following: yeast extract, 5
g; peptone, 10 g; glucose, 20 g; chloramphenicol 1.0 g; agar,
20 g; and distilled water, 1 liter. Since
S. apiospermum is
often associated with
A. fumigatus in CF patients, the culture
medium was supplemented with cycloheximide (1.0 g per liter)
as previously described (
2). This concentration of cycloheximide
inhibits the growth of most strains of
A. fumigatus, whereas
S. apiospermum tolerates cycloheximide concentrations up to
5 g per liter (
6). Aliquots (100 µl) of the samples were
plated directly or after digestion for 30 min at 37°C with
an equal volume of 2,3-dihydroxy-1,4-dithiolbutane (Digest-EUR;
Eurobio, Les Ulis, France), and this was followed by 1:10 dilution
in sterile distilled water (
2). Two plates were used for each
sample, and after incubation at 37°C, all colonies (with
a maximum of five colonies for each sample) from the primary
cultures were isolated before sporulation. All isolates were
preserved and referenced at the BCCM/IHEM Culture Collection
(Brussels, Belgium). The origin of the isolates and patient
clinical data (dates of birth, of CF diagnosis, and of first
colonization of the airways by
S. apiospermum, as well as dates
of antifungal treatments) are indicated in Tables
1 and
2. Colonization
of the airways by
S. apiospermum was defined by the isolation
of the fungus from at least three successive sputum samples
collected during a 6-month period. Bronchopulmonary infection
was defined by clinical or radiological signs associated with
positive sputum cultures and with serum specific antibodies
revealed by counterimmunoelectrophoresis using both culture
filtrate and a somatic extract of
S. apiospermum (
3).
DNA extraction.
The isolates were cultivated to stationary phase in yeast extract-peptone-dextrose
broth at 37°C for 2 weeks. After this, the mycelium was
collected, washed in sterile distilled water, and ground in
liquid nitrogen with a mortar and pestle. Total genomic DNA
was extracted as previously described (
26), using a DNeasy Plant
Mini Prep kit (QIAGEN, Courtaboeuf, France) as recommended by
the manufacturer. The DNA concentration was quantified with
a TKO 100 fluorimeter (Hoefer Scientific Instruments, San Francisco,
Calif.).
PCR amplification.
Three RAPD primersGC70 (5'-CGGCCACTGT-3'), UBC-701 (5'-CCCAACAACCC-3'), and UBC-703 (5'-CCAACCACCC-3')previously selected for their efficiency in discriminating among strains of S. apiospermum (26), were used to amplify total DNA samples. Reaction mixtures (25-µl final volume) consisted of 50 mM KCl, Triton X-100 (0.1%), gelatin (0.2 mg/ml), Tris-HCl buffer (pH 9) containing 1.5 mM MgCl2, a 200 µM concentration of each deoxynucleoside triphosphate, 5 pmol of primer, 25 ng of genomic DNA, and 1 U of Taq DNA polymerase (Appligène-Oncor, Illkirch, France). Amplifications were carried out in a Perkin-Elmer 480 thermocycler programmed for 40 cycles consisting of denaturation (1 min at 94°C), annealing (1 min at 36°C), and elongation (2 min at 72°C). Amplicons were separated by electrophoresis in 1.5% agarose gels in Tris (40 mM)-acetate (10 mM)-EDTA (0.5 mM) buffer (pH 8.0) and visualized by UV transillumination after ethidium bromide staining. Experiments were repeated twice in order to confirm the pattern differences.
Data analysis.
Data were recorded as presence or absence of each amplicon and analyzed using the NT sys-pc program (version 1.80; Exeter Software, Setauket, N.Y.). The similarity degree (SD) was calculated for each couple of genotypes according to the Jacquard coefficient (16). Grouping was carried out by the unweighted pair group method using arithmetic average (UPGMA) cluster analysis (19).

RESULTS
During the sampling period, nine CF patients were found to be
colonized by
S. apiospermum, and a total of 129 isolates were
collected, corresponding to 30 positive sputum samples. Three
primers (UBC-701, UBC-703, and GC70), previously selected for
their ability to differentiate
S. apiospermum isolates (
26),
were used to amplify the genomic DNA of these isolates. The
electrophoretic patterns of resulting amplicons allowed us to
identify 16 different genotypes, designated G1 to G16. Each
genotype corresponded to a specific combination of electrophoretic
patterns obtained with the three selected primers (Fig.
1).
Among these primers, UBC-703 was the most discriminating, allowing
the differentiation of all but two genotypes. Genotypes G1 and
G2, as well as genotypes G12 and G13, could not be differentiated
with this primer. These genotypes were differentiated only by
using primer GC70 (Fig.
1), whereas genotypes G3, G4, G5, G9,
and G10 were distinguished from the others by each of the three
primers.
Each genotype was identified in a single patient (Table
2).
In addition, a unique genotype was recovered from multiple isolates
from two transient carriers, patients P2 and P5, as well as
from successive and multiple isolates from two chronically colonized
patients (patients P3 and P7). Likewise, although a single sputum
sample was available during the sampling period for patient
P6, who was colonized by the fungus since 1992, a unique genotype
was also recovered from this patient. Two different genotypes
were detected for two of the patients, patients P4 and P9, also
chronically colonized by the fungus, whereas patients P1 and
P8 were infected by three and four genotypes, respectively (Fig.
2). Among the patients colonized by several genotypes, different
situations were observed: (i) presence of a quasi-exclusive
genotype sporadically accompanied by one or two others, corresponding
to only one (patient P1 from Angers) or two (patient P4 from
Giens) isolates; (ii) presence of two prevalent genotypes (genotypes
G11 and G12) recovered during the full sampling period, with
two additional genotypes corresponding each to only one isolate
(patient P8 from Tours); or (iii) presence of two distinct genotypes
identified successively in the two samples obtained from patient
P9, genotype G15 exclusively in the first sample and genotype
G16 in the second sample.
The phylogenetic tree revealed two clusters separated at a normalized
distance of 0.11 (Fig.
3). In each cluster, genotypes from different
geographic origins were encountered. The different genotypes
obtained from a single patient were usually closely related
or clustered. For instance, in patient P8, who developed a bronchopulmonary
infection, the four genotypes identified (genotypes G11, G12,
G13, and G14) were closely related. Likewise, genotypes G15
and G16 from patient P9 and genotypes G6 and G7 from patient
P4 were also closely related. Conversely, genotype G3 was far
from genotypes G1 and G2 (SD = 0.25), although these three genotypes
were recovered from the same patient. The most closely related
genotypes were genotypes G12 and G13 (SD = 0.93), and genotype
G9, identified in patient P6 from the Giens hospital, was the
most distant from the others (SD = 0.15).

DISCUSSION
PCR-based ribotyping was the first molecular method that was
proposed for the analysis of
Scedosporium isolates (
8,
10,
13,
24,
25). However, RAPD, which has been used successfully for
numerous epidemiological purposes in medical mycology, also
proved its efficiency for the characterization of
Scedosporium prolificans isolates (
17,
18). In a previous paper, this molecular
typing method was compared to multilocus enzyme electrophoresis
for the differentiation of strains of
S. apiospermum from different
origins, including CF patients (
26). The best results were obtained
by combining three RAPD primers, GC70, UBC-701, and UBC-703,
which also presented the best discriminatory power for
S. prolificans (
17,
18). This three-primer set was therefore used here to investigate
the molecular epidemiology of the colonization of the airways
by
S. apiospermum in nine CF patients monitored in three different
hospitals in France (Angers, Giens, and Tours). The mycological
survey of these patients resulted in 30 positive sputum samples
corresponding to 129 isolates. Sixteen genotypes were identified,
with no single genotype common to different patients, allowing
us to rule out any transcontamination. In addition, UPGMA analysis
did not reveal any clustering according to the geographic origin
of the isolates. Interestingly, similar epidemiological features
have also been reported for
Aspergillus terreus, another filamentous
fungus associated with CF (
20). Conversely, Williamson et al.
(
25), using ribotyping of isolates from 29 patients exhibiting
pulmonary
S. apiospermum infections, showed that patients from
the same respiratory medical unit, including CF patients, exhibited
one common predominant ribotype, indicating a possible common
source of infection. Likewise, the large survey of 255 CF patients
infected with
B. cepacia carried out by Mahenthiralingam et
al. (
11) demonstrated the occurrence of widely distributed epidemic
genotypes. Although most of the patients were infected with
a single strain, seven ribotypes were recovered from multiple
patients living in different geographic areas all over the world.
Despite the high polymorphism previously revealed in S. apiospermum by this three-primer set (26), a unique and specific genotype was recovered for five out of the nine patients of our cohort, including two transient carriers. Furthermore, when several genotypes were identified in specimens from the same patient, a predominant genotype was always recovered throughout the sampling period, except for patient P9. For instance, 36 of the 38 isolates obtained from the nine samples collected over 12 months from patient P1 corresponded to the same genotype, genotype G1. Likewise, most of the isolates obtained from the three samples collected over 13 months for patient P4 and from the six samples collected over 9 months for patient P8 belonged to the same genotype.
In addition, the different genotypes identified in specimens from the same patient were usually closely related. For example, genotype G2 was close to the initial genotype, genotype G1, found in patient P1. Likewise, genotypes G11, G12, G13, and G14 from patient P8 were also closely related. The only exception was genotype G3, which was found to be very far from G1 and G2 although it was also recovered from patient P1. Thus, most of the patients studied were colonized by a unique genotype, and when another genotype was detected, it was usually identified in only one clinical sample and corresponded to a unique isolate. A different situation was evidenced in the case of patient P9, for whom two genotypes were successively identified, the first disappearing to the second in a very short interval. However these two genotypes were genetically related (SD = 0.62), indicating the possible derivation of genotype G16 from genotype G15. In agreement with our results, a unique genotype was also identified in each CF patient colonized by A. terreus (20). Likewise, Mahenthiralingam et al. (11) identified only one genotype of B. cepacia from the same patient over 5 years.
Similar methods in our hands led to opposite results for the colonization of the airways of CF patients by A. fumigatus (4). An important polymorphism was revealed from one patient to another, but polymorphism was also observed between different clinical samples from the same patient or even within the same sample, thus confirming previous studies from others (12, 14, 23). This may reflect differences in the occurrence of these fungi in the environment of the patients. A. fumigatus is a widespread ubiquitous mold; all individuals are continuously exposed to the inhalation of airborne conidia belonging to different genotypes, and these conidia find a suitable environment for their development in the airways of CF patients. Conversely, S. apiospermum has been occasionally isolated from soil (5) and has never been recovered from the indoor or outdoor environments of patients (1). In addition, despite the huge biodiversity observed for A. fumigatus, a genotype common to most of the chronically colonized patients tended to settle with the ageing colonization (4), whereas no common genotype was found for patients colonized by S. apiospermum.
In conclusion, these results confirmed our previous study, which did not reveal any clustering according to the origin of the isolates. It has to be specified, however, that if RAPD is well suited for an accurate differentiation of the strains, this method is perhaps too discriminating to reveal clustering. In addition, our results demonstrated the clonality of the S. apiospermum organisms colonizing the airways. Unlike A. fumigatus, and despite the antifungal treatments, a unique genotype was almost recovered from our patients, probably in relation to the low occurrence of the fungus in the environments of the patients and its poor sensitivity to antifungal drugs (7). This study therefore reinforces the need for the development of new antifungal drugs that are more efficient against this filamentous fungus.

ACKNOWLEDGMENTS
This work was supported by a grant from the Programme Hospitalier
de Recherche Clinique du Ministère des Affaires Sociales,
de la Santé et de la Ville (PHRC 1997).

FOOTNOTES
* Corresponding author. Mailing address: Laboratoire de Biotechnologie, Unité de Biocatalyse, FRE CNRS 2230, Faculté des Sciences, 2, rue de la Houssinière, 44072 Nantes Cedex 03, France. Phone: (33) 02 51 12 56 25. Fax: (33) 02 51 12 56 37. E-mail:
Alain.Defontaine{at}chimbio.univ-nantes.fr.

Present address: Département de Biologie, Faculté des Sciences, Université Moulay Ismail, Meknès, Morocco. 

REFERENCES
1
- Beguin, H., and N. Nolard. 1994. Mould biodiversity in homes. Air and surface analysis of 130 dwellings. Aerobiologia 10:157-166.[CrossRef]
2
- Cimon, B., J. Carrère, J. P. Chazalette, J. L. Giniès, P. Six, J. F. Vinatier, D. Chabasse, and J. P. Bouchara. 1995. Fungal colonization and immune response to fungi in cystic fibrosis. J. Mycol. Med. 5:211-216.
3
- Cimon, B., J. Carrère, J. F. Vinatier, J. P. Chazalette, D. Chabasse, and J. P. Bouchara. 2000. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 19:53-56.[CrossRef][Medline]
4
- Cimon, B., F. Symoens, R. Zouhair, D. Chabasse, N. Nolard, A. Defontaine, and J. P. Bouchara. 2001. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients. J. Med. Microbiol. 50:367-374.[Abstract/Free Full Text]
5
- Cremer, G., and P. Boiron. 1996. Epidemiology and biology of Scedosporium species. J. Mycol. Med. 6:165-171.
6
- Dupont, B., L. Improvisi, and O. Ronin. 1991. Aspects épidémiologiques et cliniques des infections à Scedosporium et Pseudallescheria. J. Mycol. Med. 1:33-42.
7
- Hennequin, C., N. Benailly, C. Silly, M. Sorin, P. Scheinmann, G. Lenoir, J. L. Gaillard, and P. Berche. 1997. In vitro susceptibilities to amphotericin B, itraconazole, and miconazole of filamentous fungi isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 41:2064-2066.[Abstract]
8
- Issakainen, J., J. Jalava, E. Eerola, and C. K. Campbell. 1997. Relatedness of Pseudallescheria, Scedosporium and Graphium pro parte based on SSU rDNA sequences. J. Med. Vet. Mycol. 35:389-398.[Medline]
9
- Koch, C., and N. Hoiby. 1993. Pathogenesis of cystic fibrosis. Lancet 341:1065-1069.[CrossRef][Medline]
10
- Lennon, P. A., C. R. Cooper, L. F. L. Salkins, and S. B. Lee. 1994. Ribosomal DNA internal transcribed spacer analysis supports synonymy of Scedosporium inflatum and Lomentospora prolificans. J. Clin. Microbiol. 32:2413-2416.[Abstract/Free Full Text]
11
- Mahenthiralingam, E., M. E. Campbell, D. A. Henry, and D. P. Speert. 1996. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J. Clin. Microbiol. 34:2914-2920.[Abstract]
12
- Neuvéglise, C., J. Sarfati, J. P. Debeaupuis, H. Vu Thien, J. Just, G. Tournier, and J. P. Latgé. 1997. Longitudinal study of Aspergillus fumigatus strains isolated from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 16:747-750.[CrossRef][Medline]
13
- Rainer, J., G. S. de Hoog, M. Wedde, Y. Gräser, and S. Gilges. 2000. Molecular variability of Pseudallescheria boydii. J. Clin. Microbiol. 38:3267-3273.[Abstract/Free Full Text]
14
- Rath, P. M., F. Ratjen, and R. Ansorg. 1997. Genetic diversity among isolates of Aspergillus fumigatus in patients with cystic fibrosis. Zentbl. Bakteriol. 285:450-455.
15
- Rippon, J. W. 1988. Pseudallescheriasis, p. 651-680. In J. W. Rippon (ed.), Medical mycology. The pathogenic fungi and the pathogenic Actinomycetes, 3rd ed. W. B. Saunders, Philadelphia, Pa.
16
- Romesburg, H. C. 1984. Cluster analysis for researchers. Lifetime Learning Publications, Belmont, Calif.
17
- Ruis-Diez, B., F. Martin-Diez, J. L. Rodriguez-Tudela, M. Alvarez, and J. V. Martinez-Suarez. 1997. Use of random amplification of polymorphic DNA (RAPD) and PCR-fingerprinting for genotyping a Scedosporium prolificans (inflatum) outbreak in four leukemic patients. Curr. Microbiol. 35:186-190.[CrossRef][Medline]
18
- San Millan, R., G. Quindos, J. Garaizar, R. Salesa, J. Guarro, and J. Ponton. 1997. Characterization of Scedosporium prolificans clinical isolates by randomly amplified polymorphic DNA analysis. J. Clin. Microbiol. 35:2270-2274.[Abstract]
19
- Sneath, P. H., and R. R. Sokal. 1973. Numerical taxonomy. Freeman, San Francisco, Calif.
20
- Symoens, F., J. P. Bouchara, S. Heinemann, and N. Nolard. 2000. Molecular typing of Aspergillus terreus isolates by random amplification of polymorphic DNA. J. Hosp. Infect. 44:273-280.[CrossRef][Medline]
21
- Tadros, T. S., K. A. Workowski, R. J. Siegel, S. Hunter, and D. A. Schwartz. 1998. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum. Pathol. 29:1266-1272.[CrossRef][Medline]
22
- Travis, L. B., G. D. Roberts, and W. R. Wilson. 1985. Clinical significance of Pseudallescheria boydii: a review of 10 years' experience. Mayo Clin. Proc. 60:531-537.[Medline]
23
- Verweij, P. E., J. F. G. M. Meis, J. Sarfati, J. A. A. Hoogkamp-Korstanje, J.-P. Latgé, and W. J. G. Melchers. 1996. Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis. J. Clin. Microbiol. 34:2595-2597.[Abstract]
24
- Wedde, M., D. Müller, K. Tintelnot, G. S. de Hoog, and U. Stahl. 1998. PCR-based identification of clinically relevant Pseudallescheria/Scedosporium strains. Med. Mycol. 36:61-67.[CrossRef][Medline]
25
- Williamson, E. C. M., D. Speers, I. H. Arthur, G. Harnett, G. Ryan, and T. J. J. Inglis. 2001. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J. Clin. Microbiol. 39:47-50.[Abstract/Free Full Text]
26
- Zouhair, R., A. Defontaine, C. Ollivier, B. Cimon, F. Symoens, J. N. Hallet, J. Deunff, and J. P. Bouchara. 2001. Typing of Scedosporium apiospermum strains by multilocus enzyme electrophoresis and random amplification of polymorphic DNA. J. Med. Microbiol. 50:925-932.[Abstract/Free Full Text]
Journal of Clinical Microbiology, June 2002, p. 2108-2114, Vol. 40, No. 6
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.6.2108-2114.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Thornton, C. R.
(2009). Tracking the Emerging Human Pathogen Pseudallescheria boydii by Using Highly Specific Monoclonal Antibodies. CVI
16: 756-764
[Abstract]
[Full Text]
-
Nagano, Y., Cherie, M. B, Goldsmith, C. E, Stuart, E. J, Rendall, J., Moore, J. E
(2009). Emergence of Scedosporium apiospermum in patients with cystic fibrosis. BMJ Case Reports
2009: bcr2007119503-bcr2007119503
[Full Text]
-
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., Rinaldi, M. G., Shea, Y. R., Zaoutis, T., Kottilil, S., Walsh, T. J.
(2008). Infections Caused by Scedosporium spp.. Clin. Microbiol. Rev.
21: 157-197
[Abstract]
[Full Text]
-
Nagano, Y., Millar, B C., Goldsmith, C. E, Elborn, J S., Rendall, J., Moore, J. E
(2007). Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch. Dis. Child.
92: 607-607
[Full Text]
-
Alastruey-Izquierdo, A., Cuenca-Estrella, M., Monzon, A., Rodriguez-Tudela, J. L.
(2007). Prevalence and Susceptibility Testing of New Species of Pseudallescheria and Scedosporium in a Collection of Clinical Mold Isolates. Antimicrob. Agents Chemother.
51: 748-751
[Abstract]
[Full Text]
-
Gilgado, F., Cano, J., Gene, J., Guarro, J.
(2005). Molecular Phylogeny of the Pseudallescheria boydii Species Complex: Proposal of Two New Species. J. Clin. Microbiol.
43: 4930-4942
[Abstract]
[Full Text]
-
Schroers, H.-J., Baayen, R.P., Meffert, J.P., de Gruyter, J., Hooftman, M., O'Donnell, K.
(2004). Fusarium foetens, a new species pathogenic to begonia elatior hybrids (Begonia x hiemalis) and the sister taxon of the Fusarium oxysporum species complex. Mycologia
96: 393-406
[Abstract]
[Full Text]
-
Gibson, R. L., Burns, J. L., Ramsey, B. W.
(2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med.
168: 918-951
[Abstract]
[Full Text]